Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome: a Randomized Double-blind Placebo-controlled Clinical Trial

University of Bologna1 site in 1 country50 target enrollmentMarch 1, 2017

ConditionsNAFLD Metabolic Syndrome

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: NAFLD
Sponsor: University of Bologna
Enrollment: 50
Locations: 1
Primary Endpoint: Effect on Fatty Liver Index
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This was a double-blind, randomized, placebo-controlled clinical study aiming to assess the effect of a food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3 on liver steatosis in individuals with NAFLD and metabolic syndrome

Registry

clinicaltrials.gov

Start Date

March 1, 2017

End Date

June 1, 2018

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University of Bologna

Responsible Party

Principal Investigator

Claudio Borghi

Prof. Dr.

University of Bologna

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Effect on Fatty Liver Index

Time Frame: 3 months

We evaluated the effect on Fatty Liver Index (FLI) of 3-month assumption of a food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3, compared to either baseline and placebo